Venezuela (Bolivarian Republic of)Tuberculosis profile
Population  2015 31 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.73 (0.72–0.73) 2.3 (2.3–2.3)
Mortality (HIV+TB only) 0.18 (0.025–0.48) 0.58 (0.08–1.5)
Incidence  (includes HIV+TB) 8.9 (6.9–11) 29 (22–36)
Incidence (HIV+TB only) 0.96 (0.73–1.2) 3.1 (2.3–3.9)
Incidence (MDR/RR-TB)** 0.34 (0.19–0.49) 1.1 (0.61–1.6)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.44 (0.22–0.66) 3.1 (1.9–4.3) 3.5 (2.1–5)
Males 0.49 (0.32–0.67) 4.9 (3.7–6.1) 5.4 (4–6.8)
Total 0.94 (0.66–1.2) 8 (6.8–9.2) 8.9 (6.9–11)
TB case notifications, 2015  
Total cases notified 7 278
Total new and relapse 7 136
          - % tested with rapid diagnostics at time of diagnosis 7%
          - % with known HIV status 76%
          - % pulmonary 84%
          - % bacteriologically confirmed among pulmonary 68%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.1 (0.07–0.15)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 589 11%
          - on antiretroviral therapy 572 97%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  230
(130–320)
Estimated % of TB cases with MDR/RR-TB 3% (1.5–4.6) 12% (6.9–17)  
% notified tested for rifampicin resistance 6% 35% 592
MDR/RR-TB cases tested for resistance to second-line drugs   28
Laboratory-confirmed cases MDR/RR-TB: 43, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 31, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 80% 6 353
Previously treated cases, excluding relapse, registered in 2014 73% 223
HIV-positive TB cases, all types, registered in 2014 79% 482
MDR/RR-TB cases started on second-line treatment in 2013 53% 19
XDR-TB cases started on second-line treatment in 2013 50% 4
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (96–100)
TB financing, 2016  
National TB budget (US$ millions) <1
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data